Cystic Fibrosis clinical trials
Showing 51–98 of 98 active trials. Describe your situation to see which ones you may be eligible for.
- Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
- Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
- Regional Phenotyping of CF and Non-CF Bronchiectasis
- Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
- Impact of Sinus Surgery on Individuals With Cystic Fibrosis
- Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
- Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis
- Genetics of Insulin and Incretins in Cystic Fibrosis
- Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
- Kidney Function in People With Cystic Fibrosis in the Era of HEMT
- Sinus Disease in Young Children With Cystic Fibrosis
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
- Natural History of Noncirrhotic Portal Hypertension
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
- Natural History of Bronchiectasis
- Study of Mycobacterial Infections
- Role of Genetic Factors in the Development of Lung Disease
- Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet
- Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
- OnTrackCF: Engagement, Feasibility, and Acceptability Study
- Lung Transplant READY CF 2: CARING CF Ancillary RCT
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
- Exercise in Child Health
- Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis
- A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
- Role of Omega-DEK in Childhood Apraxia of Speech
- Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function
- Rethinking Early Airway Clearence Therapies
- Nutrition Supplement for Cystic Fibrosis
- Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers
- Verapamil Effect in Cystic Fibrosis-related Dysglycemia
- Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening
- Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
- Genetic Modifiers of Cystic Fibrosis Related Diabetes
- Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
- Feasibility of CGM Use in Hospitalized Youth
- Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
- A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
- Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
- Early Check: Expanded Screening in Newborns
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
- A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.